Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial

European Heart Journal

Volumn 22, Issue 23, 2001, Pages 2135-2137

  Ridker, P M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; PRIORITY JOURNAL; SCREENING;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CLINICAL TRIALS; HEART DISEASES; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION;

EID: 0035211591     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2990     Document Type: Editorial

References (16)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. Primary prevention of acute coronary events with lovastatin men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
3. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks?
4. Using cost-effectiveness analysis to target cholesterol reduction
5. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
6. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
7. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring trends and determinants in cardiovascular disease) Augsberg Cohort Study, 1984 to 1992
8. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
9. Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease
10. Long-term effects of Pravastatin on plasma concentration of C-reactive protein
11. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study
12. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
13. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
14. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
15. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
16. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease